Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events). FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer
- Regulatory status may accelerate FDA interactions and development review for Vir’s oncology candidate
- VIR-5500 co-developed with Astellas under a global strategic collaboration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.